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We evaluated risks associated with elevated alkaline
phosphatase in hemodialysis patients using longitudinal data
from the Dialysis Outcomes and Practice Patterns Study,
a prospective observational study of hemodialysis patients
in 12 countries. Alkaline phosphatase levels were normalized
by the upper limit of the laboratory-reported reference
range. Cause-specific hospitalization and mortality risks were
evaluated using Cox proportional hazards models, stratified
by region and adjusted for phosphorus, calcium, albumin,
parathyroid hormone, case mix, and numerous
comorbidities. The odds of high normalized alkaline
phosphatase were increased twofold in the United States
in comparison to Japan. Elevations of normalized alkaline
phosphatase were significantly associated with several
comorbid conditions, increased fractures, parathyroidectomy,
risk of hospitalization due to major adverse cardiac events,
higher all-cause cardiovascular, and infection-related
mortality risk. Our results also show that elevated serum
normalized alkaline phosphatase was associated with higher
risks of hospitalization and death in hemodialysis patients,
independent of calcium, phosphorus, and parathyroid
hormone levels.
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Altered patterns of mineral metabolism, including alkaline
phosphatase (AP), are often observed in end-stage renal disease
(ESRD) patients on hemodialysis (HD) therapy. In HD
patients, elevated levels of serum AP are associated with
secondary hyperparathyroidism (SHPT),1,2 renal osteodystro-
phy,3,4 cardiac failure, diastolic dysfunction,5 and cardiovas-
cular disease (CVD).6 Serum total AP commonly includes
isoenzymes from bones and liver, as well as kidneys, intestines,7
or leukocytes.8 Although correlations of AP isoenzyme
elevations to elevated parathyroid hormone (PTH) have been
documented, few studies have examined the risks associated
with elevated AP in HD patients. Notably, Kalantar-Zadeh
et al.9 demonstrated an increased risk of all-cause mortality
associated with higher baseline and time-varying AP levels in
HD patients, without including adjustments for elevated serum
phosphorus and calcium levels, which have been associated
with higher mortality risk.10
The present study was based on the hypothesis that
elevated AP levels are an independent marker of increased
mortality risk in HD patients. We aimed to identify the
factors and risks associated with elevated AP using long-
itudinal data from the Dialysis Outcomes and Practice
Patterns Study (DOPPS). The international nature and large
sample size of DOPPS allowed comparison of AP levels
in HD patients across 12 countries and evaluation of over
30 predictors of elevated AP. Detailed information about
cause of hospitalization and death collected by DOPPS
enabled us to assess the relationship between AP levels with
cause-specific morbidity and mortality.
RESULTS
Subject eligibility
Representing all 12 countries, 198 DOPPS I and 248
DOPPS II facilities met the inclusion criterion for these
analyses (Table 1). From these facilities, baseline norma-
lized AP (nAP) data were determined for 14,643 patients
(DOPPS I and II), and longitudinal data for 7550 patients
(DOPPS I).
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Patient demographics
In DOPPS II, country median nAP values varied from 0.63 in
Sweden to 0.81–0.82 in the United States of America (US)
and Italy (Table 1). Compared to the overall mean
percentage, the United States of America and Italy had a
significantly larger percentage of patients with nAP41.0
(32.8 and 32.9%), whereas Japan and Germany had a
significantly lower percentage (17.4 and 18.7%).
Table 2 shows significant (Po0.05) differences in the
baseline case-mix and comorbid characteristics between
mildly or markedly elevated versus normal nAP categories.
The missing nAP category had a significantly (Po0.05)
higher mean BMI (body mass index) and percentage of black
patients, and a significantly lower percentage of patients with
cancer, hypertension, hepatitis C, fistula use, or vitamin D
treatment than the non-missing category. Among a prevalent
cross-section of DOPPS II patients from countries with
sevelamer use (n¼ 1414), 23% were prescribed sevelamer,
61% calcium-based phosphate binders, and 3% other
phosphate binders, whereas 12% were not prescribed any
phosphate binder (data not shown).
Predictors of elevated nAP
Significantly (Po0.05) higher odds of mildly elevated nAP
values (1.0onAPp1.4 versusp1.0) were predicted by lower
serum phosphorus, calcium, albumin, or higher PTH
(Table 3), and were also associated with lower BMI, hepatitis
C, ascites, diabetes, CVD other than coronary artery disease
or congestive heart failure, psychiatric disorder, or no prior
parathyroidectomy (PTx) or hypertension. There was a
strong relationship between the odds of mildly elevated
nAP and time since ESRD onset, with patients nearly twice as
likely to display mildly elevated nAP if living with ESRD for
more than 9 years compared with patients living with ESRD
for less than 3 years (data not shown).
In addition to predictors of mildly elevated nAP (except a
prior PTx), the odds of markedly elevated nAP (41.4 versus
p1.0) were significantly higher in 18- to 44-year-old males,
and in patients with coronary artery disease, no cerebro-
vascular disease, gastrointestinal (GI) bleeding, peripheral
arterial disease, and recurrent cellulitis or gangrene. In a sub-
analysis of DOPPS II patients, C-reactive protein was a signi-
ficant predictor of markedly (adjusted odds ratio (AOR)¼
5.16; P¼ 0.02) but not mildly (AOR¼ 1.57; P¼ 0.4) elevated
nAP versus normal nAP. Transferrin was not a significant
predictor of mildly or markedly elevated nAP (AOR¼ 1.0
and 1.0; P¼ 0.2 and 0.3, respectively). When history of
alcohol abuse in the past 12 months (a component of the
psychiatric disease comorbid classification) was included in
a sensitivity model without psychiatric disease as a covariate,
it was significantly predictive of higher odds of mildly but not
markedly elevated nAP (AOR¼ 1.19, P¼ 0.03 and AOR¼
1.01, P¼ 0.9, respectively).
Women aged 45–59 years had significantly higher odds
of mildly or markedly elevated nAP compared with women
aged 18–44 years. A sub-analysis of women aged 45–49 and
50–59 years showed that higher odds of elevated nAP were
consistent throughout this age range (data not shown). The
odds of markedly elevated nAP were lower for all categories
of males aged X45 years, compared with men aged o45
years. In an independent linear regression model with age
and sex modeled as covariates, male HD patients had
significantly (Po0.0001) lower odds of mildly or markedly
elevated nAP values (AOR¼ 0.78 and 0.67, respectively)
compared with female patients.
The adjusted odds of mildly elevated nAP levels were
significantly lower for Japan or Europe versus North America
(Po0.0001 and P¼ 0.04, respectively). Without adjustment for
hepatitis C and other comorbidities, Japan had consistently
lower odds OR of mildly or markedly elevated AP than North
America (OR¼ 0.58 and 0.4, respectively; both Po0.0001).
Europe (compared with North America) displayed a signifi-
cantly lower unadjusted OR of mildly or markedly elevated nAP
(OR¼ 0.73, Po0.0001 and OR¼ 0.69, P¼ 0.001, respectively).
Among DOPPS II countries where sevelamer was available,
baseline use of sevelamer (compared with calcium-based
Table 1 | Descriptive statistics of baseline patient normalized AP values countrywise: DOPPS II
Baseline data from a prevalent cross-section of DOPPS II patients
Country (n facilities) n patients Country mean nAP (±s.d.) Country median nAP Patient nAP41.0 (%)
Japan (57) 1727 0.77 (0.48) 0.67 17.4*
US (57) 1671 0.99 (0.81) 0.81 32.8*
Spain (18) 557 0.89 (0.70) 0.74 24.6
Belgium (17) 466 0.85 (0.51) 0.71 26.5
Australia–New Zealand (19) 466 0.96 (1.39) 0.75 26.6
Canada (14) 407 0.89 (0.61) 0.75 24.9
Germany (14) 403 1.04 (4.94) 0.67 18.7*
France (15) 370 1.28 (5.31) 0.68 23.0
Italy (12) 351 1.05 (1.09) 0.82 32.9*
United Kingdom (12) 329 0.77 (0.50) 0.66 22.5
Sweden (13) 330 0.89 (0.96) 0.63 22.0
DOPPS, Dialysis Outcomes and Practice Patterns Study; nAP, normalized alkaline phosphatase.
The percentage of patients with nAP41.0 from each country was compared to the overall mean percentage of patients with nAP41.0 with adjustments made for
facility-clustering effects.
*Po0.05.
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phosphate binders) was associated with increased OR of mildly
(AOR¼ 1.2, P¼ 0.09) or markedly elevated nAP (AOR¼ 1.5,
P¼ 0.0001). Use of other phosphate binders versus calcium-
based phosphate binders did not significantly predict mildly
(P¼ 0.29) or markedly elevated nAP (P¼ 0.18).
Correlates of elevated nAP with hospitalization
Baseline Cox hospitalization models (normal nAP (p1.0)¼
reference) showed that mildly or markedly elevated nAP were
significantly (Po0.05) associated with a higher risk of
hospitalization caused by the following: fracture by 42 and
67%, hyperparathyroidism by 56 and 145%, liver disease by 66
and 72%, and major adverse cardiovascular events (MACE) by
22 and 25% (Figure 1). Mildly elevated nAP was associated with
a significant 76% increased risk of hospitalization due to gall
bladder. No significant association between elevated nAP and GI
hospitalization was found. Markedly elevated nAP was associated
with a significant 24% increased risk of vascular access infection.
Among DOPPS I patients hospitalized for hyperpara-
thyroidism (n¼ 148), 73 underwent recorded PTx. Of the
75 patients hospitalized for hyperparathyroidism with no
recorded PTx, 53 were from Japan, where percutaneous
ethanol injection therapy is commonly used instead of PTx to
treat hyperparathyroidism11 (information on percutaneous
Table 2 | Characteristics of study sample
All patients: DOPPS I, II
Initial cross-section: DOPPS II
Characteristics (n=14,643) nAPp1.0 (n=4855) nAP: 1.0–1.4 (n=914) nAP: X1.4 (n=676)
Females, age 18–44, % 5.3 5.10 3.8 7.5*
Females, age 45–59, % 10.5 10.2 12.3 13.6*
Females, age 60–79, % 21.5 21.2 27.8** 26.4*
Females, age 80–100, % 4.1 4.2 5.1 5.7
Males, age 18–44, % 8.2 7.7 7.1 9.6
Males, age 45–59, % 15.8 16.4 13.9* 11.1**
Males, age 60–79, % 28.7 30.3 24.5* 21.1**
Males, age 80–100, % 5.1 5.0 5.5 5.2
Black, % 11.8 8.1 11.2* 15.0**,w
Mean years with ESRD (±s.d.) 3.5 (5.2) 4.7 (5.4) 5.4 (6.0)* 5.5 (5.7)*
Mean BMI (±s.d.) 24.3 (5.6) 24.3 (5.5) 24.1 (5.5) 24.0 (5.6)
Coronary artery disease, % 40.7 41.5 48.9** 52.3**
Congestive heart failure, % 30.9 26.7 32.5* 33.4*
Hypertension, % 76.6 77.6 76.1 78.4
Other cardiovascular diseases, % 31.9 34.6 39.5* 41.4*
Cerebrovascular disease, % 16.3 17.0 17.5 18.4
Diabetes, % 36.8 32.9 40.3** 37.1*
Peripheral vascular disease, % 23.8 24.2 28.1* 31.4*
Gastrointestinal bleeding in prior 12 months, % 6.3 5.6 6.9 6.8
Lung disease, % 10.1 9.7 12.0 12.1
Neurological disorder, % 9.5 10.3 13.6* 16.1*
Psychiatric disorder, % 18.7 16.0 22.9** 26.5**
Cancer, % 10.6 11.5 10.8 11.1
Recurrent cellulitis, gangrene, % 7.2 7.6 9.5* 11.5*
HIV/AIDS, % 0.6 0.4 0.4 0.4
Hepatitis B, % 2.3 2.2 2.9 3.0
Hepatitis C, % 8.9 8.7 12.1* 14.6**
Ascites, % 1.4 0.7 1.4 4.1**
History of PTx, % 4.3 6.9 5.6 7.7
Hip fracture in last year, % 1.1 2.3 2.2 4.6*
Fistula use, % 46.3 66.8 61.5* 57.1**
Graft use, % 15.5 14.5 18.6* 21.7**
Catheter use, % 23.5 14.1 15.8 18.1*
Vitamin D use, % 44.4 52.2 54.6 56.9*
Mean serum P, mg/dl (±s.d.) 5.6 (1.8) 5.6 (1.8) 5.4 (1.7)* 5.4 (1.8)*
Mean serum Ca, mg/dl (±s.d.) 9.1 (1.0) 9.4 (0.9) 9.3 (0.9)* 9.3 (0.9)
Mean serum PTH, pg/ml (±s.d.) 285.3 (398.8) 221.3 (299.9) 338.0 (353.9)** 485.1 (619.7)**,w
Mean serum Alb, g/dl (±s.d.) 3.6 (0.5) 3.74 (0.5) 3.68 (0.5)* 3.6 (0.5)**
Mean CRP, mg/dl (±s.d.) — 0.17 (0.17) 0.20 (0.18) 0.28 (0.1)**,w
Mean total cholesterol, mg/dl (±s.d.) 171.6 (45.8) 171.2 (43.2) 165.1 (49.0)* 162.7 (42.1)**
Mean transferrin, pct (±s.d.) — 28.1 (12.8) 26.9 (12.3)* 27.0 (11.9)
Mean serum nAP (±s.d.) 0.9 (1.3) — — —
Alb, albumin; BMI, body mass index; CRP, C-reactive protein; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESRD, end-stage renal disease; nAP, normalized alkaline
phosphatase; P, phosphorus; PTH, parathyroid hormone; PTx, parathyroidectomy.
A simple T-test was used to compare the mean and percentage between the reference category (nAPp1.0) and the mildly elevated category (1.0onAPp1.4) and the
markedly elevated category (nAP41.4) (*Po0.05, **Pp0.0001), and was also used to compare the mean and percentage between 1.0onAPp1.4 and nAP41.4 (wPo0.05). In
a prevalent cross-section of the DOPPS II population, the missing nAP category (n=584) had a significantly (Po0.05) higher mean BMI and percentage of black patients, and a
significantly lower percentage of patients with cancer, hypertension, hepatitis C, fistula use, or vitamin D treatment than the non-missing category (n=6445).
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ethanol injection therapy procedures was not collected by the
DOPPS study). The mean time to hospitalization for
hyperparathyroidism for those with and without a PTx was
similar (2.02 and 2.05 years, respectively). Both subgroups
(recorded PTx and no PTx) showed reduced nAP levels from
0–4 months before to 0–4 months after hospitalization (data
not shown).
Correlates of elevated nAP with mortality
For DOPPS I and II patients (n¼ 15,141), all-cause mortality
risk was, respectively, 25 and 38% higher among patients
with mildly and markedly elevated baseline nAP versus
patients with normal nAP (both Po0.0001). Compared with
patients having normal nAP, the risk of cardiovascular death
was significantly (Po0.05) higher for patients with mildly
or markedly elevated baseline nAP (33 and 30% higher,
respectively). Infection-related mortality risk was 51% higher
(Po0.05) for patients with markedly elevated nAP compared
with patients having normal nAP. For patients who died
during the study follow-up, the mean time at risk (±s.d.)
was 1.11 (±0.85), 1.03 (±0.83), and 1.01 (±0.72) years for
all-cause, cardiovascular, and infection-related mortality,
Table 3 | Association of patient demographic, comorbidity, and laboratory characteristics with higher nAP values: DOPPS I
and II
AOR (P-value) 1.0onAPp1.4 versus nAPp1.0 AOR (P-value) nAP41.4 versus nAPp1.0
n=2476 versus 12,656 n=1872 versus 12,656
Serum phosphorus (per mg/dl) 0.93 (o0.0001) 0.90 (o0.0001)
Serum calcium (per mg/dl) 0.85 (o0.0001) 0.89 (0.0002)
Serum PTH (per 100 pg/ml) 1.08 (o0.0001) 1.13 (o0.0001)
Serum albumin (per g/dl) 0.87 (0.02) 0.63 (o0.0001)
Total cholesterol (per 10 mg/dl) 1.00 (0.001) 1.00 (0.0005)
Vitamin D 1.02 (0.76) 1.03 (0.67)
Females, age 18–44 1.00 (ref) 1.00 (ref)
Females, age 45–59 1.36 (0.002) 1.26 (0.03)
Females, age 60–79 1.19 (0.07) 0.93 (0.51)
Females, age 80–100 1.20 (0.21) 0.80 (0.16)
Males, age 18–44 1.00 (ref) 1.00 (ref)
Males, age 45–59 0.96 (0.68) 0.67 (0.0001)
Males, age 60–79 0.88 (0.18) 0.61 (o0.0001)
Males, age 80–100 1.02 (0.92) 0.61 (0.0009)
0–3 years of ESRD 1.00 (ref) 1.00 (ref)
3–9 years of ESRD 1.25 (0.0004) 1.63 (o0.0001)
49 years of ESRD 2.05 (o0.0001) 1.91 (o0.0001)
Body mass index 0.99 (0.009) 0.96 (o0.0001)
Black race 0.95 (0.52) 1.20 (0.13)
Fistula 1.00 (ref) 1.00 (ref)
Graft 1.01 (0.95) 0.92 (0.39)
Catheter 0.93 (0.36) 0.95 (0.55)
North America 1.00 (ref) 1.00 (ref)
Japan 0.55 (o0.0001) 0.38 (o0.0001)
Europe 0.80 (0.04) 0.88 (0.35)
History of PTx 0.60 (o0.0001) 0.91 (0.45)
Hepatitis B 1.03 (0.86) 1.04 (0.83)
Hepatitis C 1.35 (0.0003) 1.57 (o0.0001)
Ascites 2.11 (0.001) 3.60 (o0.0001)
Hip fracture in last year 0.91 (0.65) 1.36 (0.16)
Coronary artery disease 1.08 (0.48) 1.13 (0.02)
Cancer 0.95 (0.45) 0.91 (0.45)
Cardiovascular disease 1.25 (o0.0001) 1.25 (0.0002)
Cerebrovascular disease 0.99 (0.86) 0.84 (0.03)
Congestive heart failure 0.98 (0.71) 1.01 (0.71)
Diabetes 1.32 (o0.0001) 1.20 (0.007)
GI bleeding in last year 1.11 (0.28) 1.26 (0.03)
Hypertension 0.82 (0.0012) 0.82 (0.005)
Lung disease (not cancer) 0.95 (0.52) 1.10 (0.20)
Neurological disorder 1.13 (0.12) 1.17 (0.08)
Psychiatric disorder 1.31 (o0.0001) 1.32 (0.0002)
Peripheral arterial disease 1.09 (0.2) 1.16 (0.02)
Recurrent cellulitis or gangrene 1.13 (0.34) 1.28 (0.02)
HIV/AIDS 1.06 (0.85) 0.57 (0.19)
BMI, body mass index; ESRD, end-stage renal disease; GI, gastrointestinal tract; nAP, normalized alkaline phosphatase; PTH, parathyroid hormone; PTx, parathyroidectomy;
ref, reference group.
Multivariate logistic regression models were used to determine the adjusted odds ratio (AOR) and P-value with all variables included in the same model; models accounted for
facility-clustering effects.
The bold numbers denote statistically significant findings.
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respectively. For patients who survived, the mean follow-up
was 1.60 (±0.92) years.
Sensitivity analysis using a time-dependent model for
DOPPS I patients (n¼ 7550) confirmed a higher risk of all-
cause, cardiovascular, and infection-related mortality asso-
ciated with above-normal nAP (Figure 2). Further sensitivity
analyses showed that when patients with baseline hepatitis B,
hepatitis C, ascites, or hip fractures within the previous
year were excluded from mortality models, the sample size
was reduced by 12.5%, but the relative risk of all-cause,
cardiovascular, or infection-related death did not change
significantly in baseline or time-dependent models (data not
shown). This suggests that the association between elevated
nAP and increased mortality risk was not because of poten-
tially confounding effects of baseline liver disease or bone
repair.
DISCUSSION
Although AP is a commonly collected laboratory measure,
this is the first study to provide a description of AP levels in a
large international patient population and identify numerous
HD patient characteristics associated with elevated AP. This
study establishes a strong relation between elevated nAP and
higher risk of hospitalization and mortality, independent of
the effects of serum phosphorus, calcium, and PTH.
The observational nature of the DOPPS data and non-
uniformity of AP values limited the study. Because associa-
tions between elevated AP and both predictors and outcomes
cannot lead to any conclusions about causality, the large
international sample helped strengthen our findings by
making multiple adjustments for potentially confounding
variables possible and by increasing variation in AP
measurements and dialysis practices across the DOPPS
countries. The use of nAP made meaningful analyses possible
across facilities with large differences in laboratory AP
reference ranges. Normalizing by the upper limit of the
laboratory reported reference range allowed easy interpreta-
tion, as values 41.0 were abnormally high.
Substantial variation and significant differences in AP
levels, even after multivariate adjustments, were seen across
the DOPPS countries and regions. To our knowledge, this is
the first study to demonstrate higher OR of elevated AP
among North-American HD patients compared with Japa-
nese and European patients. Removing the hepatitis C
adjustment did not substantially modify the relative OR of
elevated AP between regions, even though hepatitis C is more
prevalent among Japanese HD patients.12 As Japanese ESRD
patients on HD display better survival rates than US
patients,12 it is possible that lower AP levels in Japan reflect
better ESRD management practices.
Our study explored the relationship between age and AP
levels in both sexes. Because the minimum age was 18 years,
and the median age was 460 years, the potentially
confounding effect of elevated AP during adolescence13 was
not relevant to the DOPPS population. In female post-
menopausal HD patients, previous studies have shown mild
elevations in serum total AP and large increases in bone-
specific AP levels compared with premenopausal or meno-
pausal women.14,15 In our study, perimenopausal women had
higher OR of elevated AP than premenopausal patients or
HD patients 460 years old. As elevated AP levels are a
marker for higher bone turnover rates,16 these findings
suggest that female HD patients between the ages of 45 and
60 may have a higher risk of increased bone turnover.
Consistent with the higher average AP levels in female versus
male HD patients determined by Basile et al.,17 in the DOPPS
population, males of all ages had lower OR of elevated nAP
than females.
This study found that elevated nAP was strongly
associated with increased overall mortality risk in both
baseline and time-dependent models, confirming results
from a study by Kalantar-Zadeh et al.9 Although prior
analyses only adjusted for PTH level, our study shows that
elevated nAP levels were independently associated with an
increased risk of mortality after adjustment for baseline or
time-varying phosphorus, calcium, and PTH, which several
studies have shown are associated with increased mortality
risk.9,10 Higher AP levels were associated with lower serum
albumin and higher infection-related mortality, suggesting
that patients with higher AP had poor nutritional status,
inflammation, and were susceptible to severe infections.
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Figure 1 | Associations between baseline nAP and risk
of fracture, hyperparathyroid, liver, gall bladder, GI, or
MACE-related hospitalizations: DOPPS I and II. Cox models
were used to find the HR (bar) of hospitalization outcomes
associated with each category of baseline nAP values, with
95% confidence intervals (whiskers) shown. All models were
stratified by region (North America, Europe, Japan) and
adjusted for baseline case-mix, comorbid, laboratory values,
and facility-clustering effect. Independent models were run for
different causes of hospitalization, based on reported diagnoses
or procedures, such as fracture, parathyroidectomy (surgical or
by injection), liver (viral hepatitis, liver failure, ascites, pancreatitis,
or liver biopsy), gall bladder (gall bladder disease or surgery),
GI (GI bleeding, gastritis/peptic ulcer, gastroenteritis, or gastric
surgery/resection), MACE (acute myocardial infarction, stroke,
amputation, coronary bypass graft surgery, peripheral arterial
bypass surgery, or carotid endarterectomy40), and VA infection.
GI; gastrointestinal tract, HR; hazard ratio, MACE; major adverse
cardiovascular event, nAP; normalized alkaline phosphatase,
VA; vascular access.
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However, correction for baseline laboratory measurements
and numerous comorbidities suggests that elevated nAP is
not simply a marker for poor health in HD patients.
Predictors of elevated nAP identified from the DOPPS
sample, and results from hospitalization and mortality
models, point to the role of elevated AP in the development
of renal osteodystrophy and inflammation due to liver
disease or, possibly, metabolic syndrome. Elevated PTH levels
are known to correlate well with elevated AP9,18,19 and with
the development of high bone turnover20 in HD patients.
Although elevated serum AP and PTH are both indicators
suggestive of poor bone health in HD patients,21 our study
offers further support for the role of elevated AP in the
development of renal osteodystrophy due to SHPT. During
the first year of HD therapy, elevated AP and PTH levels are
independently associated with an increased risk of PTx.1,2
In the DOPPS population, low calcium and elevated PTH
levels were significant predictors of elevated nAP. Elevated
baseline nAP was associated with a significantly higher risk
of hospitalization for surgical or medical PTx (we interpret
admission for hyperparathyroidism to likely indicate a PTx
by injection). Increased time with ESRD has been associated
with increased OR of osteodystrophy21 and disregulation
of calcium and PTH.10 In the DOPPS population, higher
OR of elevated AP were predicted by more time with ESRD
(43 years). Patients with elevated nAP displayed a signi-
ficantly higher risk of hospitalization due to fractures,
suggesting poorer bone health.
DOPPS findings suggest that AP may contribute to
increased risks of cardiovascular hospitalization and morta-
lity events in HD patients. Chronic kidney disease itself
has been shown to be a risk factor for CVD. CVD mortality
risk is 10–30 times higher for chronic dialysis patients than
for the general population.22 Increased CVD levels may be
related to high bone turnover due to SHPT1 and subsequent
vascular calcification.23 Elevated AP levels in HD patients have
been linked to the development of SHPT, left ventricular
hypertrophy,6 and increased risk of congestive heart failure.5
These findings are consistent with results from the DOPPS
population where patients with baseline comorbid coronary
artery disease, other CVDs, or peripheral arterial disease were
significantly more likely to have elevated AP values, and
highly elevated nAP levels were associated with an increased
risk of hospitalization due to MACE. Elevated nAP levels were
significantly associated with cardiovascular mortality risk in
both baseline and time-dependent models. These associations
were independent of serum phosphorus, calcium, or PTH
levels or baseline indicators of cardiovascular comorbidity.
This study also examined the effects of common methods
used to control SHPT on elevated AP levels. Vitamin D
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Figure 2 | Associations between baseline (DOPPS I and II) or time-dependent (DOPPS I) nAP values and risk of all-cause,
cardiovascular, or infection-related mortality. Cox models were used to find HR (line) and 95% confidence intervals (whiskers) of
all-cause and cause-specific mortality outcomes associated with increasing baseline (top panels) or time-dependent (bottom panels) nAP
values. Bars indicate the distribution of nAP values. An nAP value greater than 1.0 indicates an AP value above the upper limit of the
laboratory reference range. All models were stratified by region (North America, Europe, Japan) and adjusted for facility-clustering effects,
baseline case-mix, comorbid, and baseline or time-varying laboratory values. Outcome events were categorized based on reported cause of
death, such as all-cause, cardiovascular-related (death due to acute myocardial infarction, cardiac arrhythmia, cerebrovascular accident,
cardiac arrest, ischemic brain damage, mesenteric infarction, or septicemia due to peripheral vascular disease), and infection-related
mortality (death due to septicemia due to vascular access, peritonitis, or other cause; bacterial, fungal, other pulmonary infection;
cytomegalovirus or other viral infection; tuberculosis, AIDS, or other infection). HR; hazard ratio, nAP; normalized alkaline phosphatase.
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administration (a recommended method for controlling
SHPT21 and bone-specific AP24) did not predict lower OR
of elevated nAP in either adjusted (Table 3) or unadjusted
models (results not shown). However, this observation may
be confounded by vitamin D use for patients with higher
nAP. PTx, another common method for controlling SHPT,
may result in an eventual decline in both PTH and AP levels,
but hungry bone syndrome can lead to a brief spike in bone
AP levels after a PTx.25,26 In baseline regression models,
significantly lower OR of mildly elevated nAP were associated
with a prior PTx, but a pattern of briefly elevated nAP levels
following hospitalization for PTx could not be demonstrated
in DOPPS I data, where AP measurements were collected
every 4 months.
Sevelamer and cinacalcet are often used for controlling
mineral metabolism in HD patients. Previously, a prospec-
tive, randomized controlled trial showed that patients treated
with sevelamer had significant elevations in AP, compared
with patients given calcium acetate.27 Elevated PTH levels,
which correlated with higher AP levels, have also been
observed with sevelamer versus calcium-based phosphate
binder use.28,29 In the large international DOPPS sample,
sevelamer versus calcium-based phosphate binder use was
associated with a nearly 30% higher OR of elevated nAP after
adjustment for PTH. Although cinacalcet has been shown to
significantly reduce AP levels in HD patients,30 and may be
associated with hypocalcemia and hungry bone syndrome in
some HD patients,31,32 as only 10 patients in the DOPPS II
population were prescribed cinacalcet, it was not possible to
examine its relationship with AP in the current study.
Although a prior study found that HD patients with
elevated serum AP have a lower fraction of liver AP
isoenzyme than HD patients without elevated AP,7 DOPPS
findings suggest that elevated AP levels may have hepatic
etiology in some patients. In our study, hepatitis C was a
strong predictor of elevated AP. Additionally, low serum
albumin, ascites, and a history of alcoholism, all potential
indicators of liver disease, were significantly associated with
elevated AP. Elevated nAP was also significantly associated
with a higher risk of liver-related hospitalization. On the
other hand, elevated AP in the general population has been
associated with both elevated BMI33 and elevated C-reactive
protein levels,34 and it has been suggested that metabolic
syndrome and related steatic hepatosis (i.e., liver AP) may
explain this constellation. In the DOPPS HD population,
higher nAP was significantly associated with higher
C-reactive protein levels, but higher BMI and hypertension
were associated with lower OR of elevated AP. Thus, the
increased AP in HD patients does not appear to be because
of steatic hepatosis. Additionally, a sensitivity analysis
that excluded patients with hepatitis B, hepatitis C, or ascites
from the models still found that the risks of all-cause or
infection-related mortality were strongly associated with
elevated AP levels. Together, this suggests that not all
nAP elevations seen in the DOPPS were because of elevated
liver-specific AP.
Intestinal AP levels have been found to be elevated by 15%
in HD patients,35 accounting for mild elevations in serum
total AP.36,37 However, the DOPPS did not test tissue-specific
AP isoenzyme levels or conduct other liver enzyme tests such
as gamma-glutamyltransferase, aspartate, or alanine amino-
transferase levels. Without this data, it is impossible to fully
understand the contributions of tissue-specific AP to the nAP
elevations in our study, or whether the increased clinical risk
associated with nAP was associated with bone, hepatic, or
intestinal AP.
The present findings indicate that AP levels in HD patients
are closely correlated to other markers of altered bone
mineral metabolism. Independent of the effects of these other
factors, elevated AP is associated with an increased risk of
both cardiovascular and infection-related hospitalization and
death. Although specific AP isoenzymes were not studied, we
conclude that elevations in serum total AP should be
considered as an indicator of a higher risk of morbidity
and mortality. This observational work strongly supports the
need for future trials to further define the clinical utility of
AP. The ease of availability and relatively low cost of AP
measurement makes it an attractive measure for monitoring
the care of HD patients.
MATERIALS AND METHODS
Data were from DOPPS I (1996–2001) and DOPPS II (2002–2004), a
prospective observational study of over 29,000 patients randomly
selected from facilities in 12 countries (Table 1). The DOPPS
sampling plan and study methods have been described pre-
viously.38,39 Patient information was collected without identifiers,
and consent was obtained as required from local or national ethics
committees or institutional review boards. All patients were over 18
years of age at study enrollment.
Baseline AP reference ranges were reported by the DOPPS
facilities and were updated annually. Facility and patient data were
excluded from this study if the facility (1) did not report a
laboratory AP reference range, (2) the upper limit of the AP
reference range changed during the study, or (3) the facility median
AP value was more than twofold greater than the midpoint of the
laboratory-reported AP reference range. Because laboratory-
reported AP reference ranges varied across DOPPS countries
and phases (Figure 3), analyses used nAP values calculated as the
ratio of a patient’s AP measurement divided by the upper limit of
the facility’s laboratory-reported reference range. Baseline nAP
values were calculated for all DOPPS patients, but longitudinal nAP
values, updated every 4 months, were only available for DOPPS I
patients. All nAP values were categorized as normal (nAPp1.0),
mildly elevated (1.0onAPp1.4), or markedly elevated (nAP41.4).
Major outcomes included hospitalization events (categorized based
on reported diagnoses or procedures, such as fracture, PTx,
liver, gall bladder (disease or surgery), GI, MACE40) or vascular
access infection and mortality events (categorized by the reported
causes of death as all-cause, cardiovascular-related, or infection-
related mortality).
Standard descriptive statistics were used to characterize the
prevalent cross-section of DOPPS I and II patients (n¼ 14,643) at
baseline. Among a prevalent cross-section of DOPPS II patients, a
simple T-test was used to identify significant differences between
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nAP categories and between patients with missing (n¼ 584) and
non-missing (n¼ 6445) nAP values.
Logistic regression models accounted for facility-clustering
effects using generalized estimating equations with the assumption
of a compound symmetry covariance structure41 to identify signi-
ficant predictors of mildly or markedly elevated nAP. Using only
DOPPS II data (n¼ 9948), logistic regression tested the association
between mildly and markedly elevated nAP and C-reactive protein
and transferrin, adjusting only for region and facility-clustering
effects. Logistic regression also tested for an association between
elevated AP (nAP41.0 versus nAPp1.0) and the use of sevelamer,
calcium-based, or other phosphate binders in DOPPS II, excluding
patients from countries where sevelamer was not available (Japan,
Belgium, New Zealand, and Australia). Cox proportional hazards
models (n¼ 14,643) tested for associations between elevated nAP
and the cause-specific hospitalization or mortality risks. Cox models
were stratified by region (North America, Japan, or Europe), and
accounted for facility-clustering effects using robust standard
estimates based on the sandwich estimator.42 Unless otherwise
specified, all models were adjusted for the baseline covariates listed
in Table 2.
Two sensitivity analyses used Cox models to determine (1) the
association between mortality and time-varying nAP values from
DOPPS I (n¼ 7550) and (2) the association between elevated nAP
values and mortality risk in a subset of the DOPPS I and II
population which excluded patients with baseline hepatitis B,
hepatitis C, ascites, or hip fractures within the previous year.
Additionally, among patients hospitalized for hyperparathyroidism
during the DOPPS I follow-up period (n¼ 149), standard descriptive
statistics were used to describe changes in nAP levels from 0 to
4 months pre-PTx versus 0–4 months or X6 months post-PTx.
All analyses were performed using the SAS statistical package
(version 9.1; SAS Institute, Cary, NC, USA). The authors have
followed the suggestions of the STROBE Statement guidelines for
reporting observational studies.43
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